Open-label study to evaluate the pharmacodynamics, clinical efficacy, and safety of meropenem for adult bacterial meningitis in Japan
| Autor: | Satoshi Iwata, Yasushi Suzuki, Tetsuyuki Hirayama, Tomohiro Takita, Shigeru Sato, Jun Ochiai, Yuka Yamagishi, Takayuki Sato, Yasuo Iwasaki, Yoshihisa Fukushima, Jun-ichi Niwa, Satoshi Kawabata, Rei Kobayashi, Masayuki Minami, Katsuro Shindo, Hiroshige Mikamo, Miki Ueda, Satoshi Kamei, Kazuto Yoshida, Naoki Hayashi, Akihiko Morita, Nobuo Araki, Hiroshi Kuroda |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Microbiology (medical)
Adult Male medicine.medical_specialty Staphylococcus Microbial Sensitivity Tests medicine.disease_cause Meropenem Gastroenterology Meningitis Bacterial Minimum inhibitory concentration Cerebrospinal fluid Japan Internal medicine Streptococcus pneumoniae polycyclic compounds Medicine Humans Pharmacology (medical) Adverse effect Aged biology business.industry Middle Aged Staphylococcal Infections biology.organism_classification Anti-Bacterial Agents Infectious Diseases Streptococcus salivarius Treatment Outcome Staphylococcus aureus Pharmacodynamics Anesthesia Female Thienamycins business medicine.drug |
| Zdroj: | Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy. 20(9) |
| ISSN: | 1437-7780 |
| Popis: | The aim of this study was to assess the efficacy, safety, and concentration of meropenem in cerebrospinal fluid when meropenem (2 g every 8 h) was administered to Japanese adult patients with bacterial meningitis. Five Japanese patients (mean age 60.6 years [range 35e71]) were enrolled. Infection with Streptococcus pneumoniae (three patients), Streptococcus salivarius (one patient), and Staphylococcus aureus (one patient) was confirmed by cerebrospinal fluid culture. Meropenem (2 g every 8 h) was administered to all five patients. Treatment duration ranged from 14 to 28 days (mean 22.6 days). All the patients were successfully treated. The concentration of meropenem in cerebrospinal fluid ranged from 0.27 to 6.40 mg/ml up to 8.47 h and was over 1 mg/ml 3 h after starting meropenem infusion. In each patient, the present study confirmed for the first time that the concentration of meropenem in cerebrospinal fluid exceeded the minimal inhibitory concentration for these pathogens. Eleven clinical and laboratory adverse events considered to be related to meropenem were observed in all patients, but no serious adverse event and no discontinuance of treatment due to adverse events occurred. Thus meropenem appeared to be a well-tolerated and effective agent for Japanese adult patients with bacterial meningitis. 2 g every 8 h of meropenem was delivered to CSF and its concentration was exceed in MICs for the detected pathogens. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect